Luspatercept
- Generic Name
- Luspatercept
- Brand Names
- Reblozyl
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1373715-00-4
- Unique Ingredient Identifier
- AQK7UBA1LS
- Background
Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood transfusions. Lu...
- Indication
Luspatercept is indicated for the treatment of:
- Associated Conditions
- Anemia
- Associated Therapies
- -
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 360
- Registration Number
- NCT05949684
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Community Cancer Institute, Clovis, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 200
- Registration Number
- NCT05931718
- Locations
- 🇮🇹
Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-03-12
- Target Recruit Count
- 36
- Registration Number
- NCT05925504
- Locations
- 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT05891249
- Locations
- 🇮🇳
All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳Local Institution - 0011, New Delhi, Delhi, India
🇮🇳Vedanta Institute Of Medical Sciences, Ahmedabad, Gujarat, India
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 70
- Registration Number
- NCT05732961
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 249
- Registration Number
- NCT05664737
- Locations
- 🇬🇷
Local Institution - 0007, Larissa, E, Greece
🇬🇷Local Institution - 0006, Athens, Greece
🇬🇷Local Institution - 0009, Goudi, Greece
A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 90
- Registration Number
- NCT05567458
- Locations
- 🇨🇳
Local Institution - 0002, Maoming, Guangdong, China
🇨🇳Local Institution - 0005, Shenzhen, Guangdong, China
🇨🇳Local Institution - 0007, Liuzhou, Guangxi, China
Efficacy and Safety of Luspatercept: A Study by Fondazione Italiana Sindromi Mielodisplastiche
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2023-02-15
- Target Recruit Count
- 215
- Registration Number
- NCT05520749
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Milan, Rozzano, Italy
Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Bing Han
- Target Recruit Count
- 90
- Registration Number
- NCT05399732
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 70
- Registration Number
- NCT05181592
- Locations
- 🇩🇪
Onkologische Schwerpunktpraxis Heidelberg, Heidelberg, Germany
🇩🇪Gemeinschaftspraxis Hämatologie/Onkologie Magdeburg, Magdeburg, Germany
🇪🇸Hospital General Universitario Gregorio Marañón, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.